As CGP testing rates increase, community oncology practices are choosing to implement in-house testing. Many factors influence their decision on a suitable solution including, but not limited to panel content and attributes, oncologists’ preferences, lab expertise, and regulatory and reimbursement requirements.
An expert panel discussion with a community-based pathologist, oncologist, and laboratory director will address: 1. Parameters for consideration in assay selection (IVD vs LDT, RNA + DNA content, ease of implementation) 2. Implementation data, process and feedback from one community site’s experience with the FDA-approved TruSight™ Oncology Comprehensive 3. Value to network oncologists and patients
